EA200970360A1 - OMEGA-3 FATTY ACIDS AND MEANS FOR THE TREATMENT OF DYSLIPIDEMIA TO REDUCE APRO-V LEVELS - Google Patents

OMEGA-3 FATTY ACIDS AND MEANS FOR THE TREATMENT OF DYSLIPIDEMIA TO REDUCE APRO-V LEVELS

Info

Publication number
EA200970360A1
EA200970360A1 EA200970360A EA200970360A EA200970360A1 EA 200970360 A1 EA200970360 A1 EA 200970360A1 EA 200970360 A EA200970360 A EA 200970360A EA 200970360 A EA200970360 A EA 200970360A EA 200970360 A1 EA200970360 A1 EA 200970360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
reduce
dyslipidemia
omega
levels
treatment
Prior art date
Application number
EA200970360A
Other languages
Russian (ru)
Inventor
Рулоф М. Л. Ронген
Роберт А. Шалвиц
Дуглас Клинг
Ральф Т. мл. Дойл
Original Assignee
Релайэнт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Релайэнт Фармасьютикалз, Инк. filed Critical Релайэнт Фармасьютикалз, Инк.
Publication of EA200970360A1 publication Critical patent/EA200970360A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ применения комбинированного введения или стандартной дозировки комбинации средства для лечения дислипидемии и омега-3 жирных кислот для снижения уровней аполипопротеина-В. Данные способы, в частности, можно применять при лечении пациентов с гиперхолестеринемией, гипертриглицеридемией, смешанной дислипидемией, коронарной болезнью сердца (CHD), сосудистыми заболеваниями, атеросклеротическими заболеваниями и связанными с ними состояниями, и для предупреждения или уменьшения сердечно-сосудистых, сердечных и сосудистых явлений.A method of using a combined administration or unit dosage of a combination agent for treating dyslipidemia and omega-3 fatty acids to reduce apolipoprotein-B levels. These methods, in particular, can be used in the treatment of patients with hypercholesterolemia, hypertriglyceridemia, mixed dyslipidemia, coronary heart disease (CHD), vascular diseases, atherosclerotic diseases and related conditions, and to prevent or reduce cardiovascular, cardiac and vascular phenomena .

EA200970360A 2006-10-10 2007-10-10 OMEGA-3 FATTY ACIDS AND MEANS FOR THE TREATMENT OF DYSLIPIDEMIA TO REDUCE APRO-V LEVELS EA200970360A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85028006P 2006-10-10 2006-10-10
PCT/US2007/021631 WO2008045465A1 (en) 2006-10-10 2007-10-10 Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels

Publications (1)

Publication Number Publication Date
EA200970360A1 true EA200970360A1 (en) 2009-10-30

Family

ID=39283166

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200970359A EA018734B1 (en) 2006-10-10 2007-09-07 STATIN AND OMEGA-3 FATTY ACIDS FOR REDUCTION OF Apo-B LEVELS
EA200970360A EA200970360A1 (en) 2006-10-10 2007-10-10 OMEGA-3 FATTY ACIDS AND MEANS FOR THE TREATMENT OF DYSLIPIDEMIA TO REDUCE APRO-V LEVELS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200970359A EA018734B1 (en) 2006-10-10 2007-09-07 STATIN AND OMEGA-3 FATTY ACIDS FOR REDUCTION OF Apo-B LEVELS

Country Status (10)

Country Link
EP (1) EP2089014A4 (en)
JP (1) JP2010505956A (en)
KR (1) KR20090080070A (en)
CN (2) CN101553221A (en)
AU (1) AU2007307007A1 (en)
BR (1) BRPI0719182A2 (en)
CA (1) CA2672919A1 (en)
EA (2) EA018734B1 (en)
MX (1) MX2009003921A (en)
WO (1) WO2008045465A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
EP2083622A4 (en) * 2006-10-18 2009-12-09 Reliant Pharmaceuticals Inc Omega-3 fatty acids for reduction of lp-pla2 levels
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
DK2596786T3 (en) 2009-02-10 2020-02-24 Amarin Pharmaceuticals Ie Ltd Use of eicosapentaenoic acid ethyl ester for the treatment of hypertriglyceridemia
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
HUE051916T2 (en) 2009-04-29 2021-04-28 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition and methods of using same
SG177254A1 (en) * 2009-06-15 2012-02-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
AU2013282394B2 (en) 2012-06-29 2018-04-26 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CN102824636A (en) * 2012-08-15 2012-12-19 四川大学 Pharmaceutical composition containing statins and polyunsaturated fatty acid and application thereof
JP6227535B2 (en) * 2012-08-30 2017-11-08 株式会社三和化学研究所 Preventive or therapeutic agent for dyslipidemia
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
MA39319A1 (en) * 2014-02-05 2017-07-31 Mitsubishi Tanabe Pharma Corp Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular disease
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (en) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 Compositions and Methods for Lowering Triglycerides in a Subject Having Reduced Kidney Function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102296068B1 (en) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 Methods of Reducing the Risk of a Cardiovascular Event in a Subject
KR20240012390A (en) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 How to Reduce Your Risk of Heart Failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014359A1 (en) * 2001-03-16 2004-02-19 Thomas Jefferson University Regulation of apob in treatment and drug screening for cardiovascular and metabolic disorders or syndromes
JP2008522970A (en) * 2004-12-06 2008-07-03 レリアント ファーマスーティカルズ インコーポレイテッド Omega-3 fatty acids and dyslipidemic agents for lipid therapy
CN101495106A (en) * 2005-07-18 2009-07-29 瑞莱恩特医药品有限公司 Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof

Also Published As

Publication number Publication date
CN101553221A (en) 2009-10-07
EP2089014A4 (en) 2009-12-09
KR20090080070A (en) 2009-07-23
JP2010505956A (en) 2010-02-25
WO2008045465A1 (en) 2008-04-17
EA200970359A1 (en) 2009-10-30
AU2007307007A1 (en) 2008-04-17
CA2672919A1 (en) 2008-04-17
CN101553220A (en) 2009-10-07
MX2009003921A (en) 2009-08-31
BRPI0719182A2 (en) 2014-10-21
EA018734B1 (en) 2013-10-30
EP2089014A1 (en) 2009-08-19

Similar Documents

Publication Publication Date Title
EA200970360A1 (en) OMEGA-3 FATTY ACIDS AND MEANS FOR THE TREATMENT OF DYSLIPIDEMIA TO REDUCE APRO-V LEVELS
NO20073456L (en) Omega-3 fatty acids and dyslipidemic agent for lipid therapy
SMT201300095B (en) Use of the ethyl ester of eicosapentaenoic acid to treat hypertriglyceridemia
AR109605A2 (en) METHOD FOR TREATING PERIPHERAL VASCULAR DISEASES, COMPOSITION AND USE
MX2009003920A (en) Statin and omega-3 fatty acids for reduction of apo-b levels.
NZ624963A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
BRPI0414455A (en) Methods for Using Regenerative Cells to Treat Peripheral Vascular Disease and Related Disorders
AR058359A1 (en) COMBINATIONS
EA201001365A1 (en) IMIDAZO [1,2-b] DERIVATIVES OF PYRIDAZINE INTENDED FOR THE TREATMENT OF DISEASE MEDIATED C-MET TYROSINKINASE
JP2006501240A5 (en)
NO20064186L (en) Substituted pyrazoline compositions to reduce blood triglycerides
EA200870254A1 (en) METHOD OF TREATING INFLAMMATORY DISEASES
WO2009004995A1 (en) Method of fixing and expressing physiologically active substance
DE602006014691D1 (en) DIAGNOSIS, TREATMENT AND PREVENTION OF VASCULAR DISEASES USING IL-1alpha AUTOANTIC BODIES
NO20064755L (en) combination therapy
ATE447973T1 (en) COMBINATION THERAPY WITH AZD-2171
CN101249108B (en) Royal jelly acidic composition, preparation and uses thereof
ATE409039T1 (en) COMBINATION THERAPY AGAINST CANCER DISEASES WITH AZD2171 AND ZD1839
Nasrat et al. A therapeutic answer for the controversy of insulin cardio-protection among dysglycemic patients
ATE407925T1 (en) 1,4-DIHYDROPYRIDINE COMPOUNDS, PHARMACEUTICAL COMPOUNDS, AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
Shimpi et al. Role of Extra Corporeal Shock Wave Therapy (ESWT) in the Management of Peyronie's Disease: A Preliminary Report
RU2010144554A (en) MEANS FOR PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
Ramesh et al. JAULAKAVACHARANA (HIRUDOTHERAPY): A UNIQUE PARA SURGICAL MEASURE
RU2007119229A (en) METHOD FOR PHOTODYNAMIC TREATMENT OF TUMORS
RU2009117809A (en) METHOD FOR TREATING VAGINAL INFECTIONS